| 证券代码：600109 | 证券简称：国金证券 | | 公告编号：临 | 2025－38 | | --- | --- | --- | --- | --- | | 债券代码：115414 | 债券简称：23 | 国金 04 | | | 国金证券股份有限公司 董事会 二〇二五年五月二十七日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 国金证券股份有限公司（以下简称"本公司"）于 2023 年 5 月 26 日发行了国金证券股份有限公司 2023 年面向专业投资者公开发行 公司债券(第三期)（债券简称：23 国金 04、债券代码：115414）, 发行总额为人民币 10 亿元，票面利率为 3.08%，发行期限为 3 年。 详 见 公 司 于 2025 年 5 月 19 日 登 载 于 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn）的《国金证券股份有限公司 2023 年面向 专业投资者公开发行公司债券(第三期)2025 年付息公告》。 2025 年 5 月 26 日，本公司"23 国金 ...

Pharmaceutical Sector - The pharmaceutical sector in China is showing strong performance, with significant transactions such as the $1.25 billion deal enhancing market confidence in the quality and market value of Chinese innovative drugs [1] - Chinese pharmaceutical companies are increasingly making their mark in global licensing transactions and showcasing their clinical pipeline potential at major conferences like ASCO [2] - The outlook for the pharmaceutical sector is optimistic, with expectations of a reversal in market trends by 2025, driven by innovative drugs and the recovery of left-side sectors [1][2] Biopharmaceuticals - GSK announced FDA approval for mepolizumab as an additional maintenance treatment for poorly controlled chronic obstructive pulmonary disease (COPD) patients, with projected global sales of €1.784 billion in 2024 [3] - There is a growing interest in IL-5 targeted drugs, with several domestic companies already engaged in this area [3] Medical Services & Consumer Healthcare - Alcon reported Q1 2025 surgical business net sales of $1.338 billion, a 1% year-on-year decline, but a 2% increase at constant exchange rates [4] - Vision care business net sales reached $1.106 billion in Q1 2025, reflecting a 1% year-on-year growth, driven by innovations in contact lenses [4] Medical Devices - Johnson & Johnson Medical launched the SOUNDSTAR CRYSTAL ultrasound catheter in the U.S. for cardiac ablation procedures, indicating a rich pipeline of innovative products [5] - There is a strong long-term demand trend for innovative medical devices, with a focus on leading companies that are expected to rapidly scale new products [5] Pharmacies - A recent initiative by multiple government departments aims to enhance the health promotion functions of retail pharmacies, indicating a supportive policy environment for non-drug product expansion [6] - Continuous optimization of industry regulations and the implementation of drug traceability measures are expected to create a more favorable environment for pharmacies [6]

Core Viewpoint - The report highlights the violations by Jiangxi Mubang High-Tech Co., Ltd. regarding the improper use of raised funds and non-operational fund occupation by related parties, necessitating corrective actions [1][11]. Group 1: Background and Findings - The special on-site inspection was conducted by Guojin Securities to investigate the misuse of raised funds and non-operational fund occupation by controlling shareholders and related parties [1]. - Abnormalities in prepaid accounts were noted, prompting the inspection from April 22 to April 30, 2025, and from May 12 to May 16, 2025 [1]. - The inspection revealed that funds were improperly used for non-investment projects, with a total of 261.44 million yuan misused, of which 229.68 million yuan occurred in 2024 [2][11]. Group 2: Specific Violations - In February 2024, 20 million yuan was transferred to the controlling shareholder through a series of transactions, constituting a violation of fund usage [3]. - In July, August, September, and November 2024, a total of 101.94 million yuan was prepaid to construction units, with part of the funds being used to repay loans and transferred to the controlling shareholder [3]. - In February 2025, 15 million yuan was improperly used from the raised funds for operational purposes [4]. Group 3: Recommendations and Corrective Actions - The company is required to report the amounts and periods of fund occupation by controlling shareholders and related parties within one month of the annual report disclosure [8]. - A qualified accounting firm should be engaged to verify the calculation of fund occupation fees and ensure compliance with disclosure obligations [8]. - The company must develop a solution for the improper use of raised funds within three months of the annual report disclosure and strengthen internal controls to prevent future violations [8][11].

近日，105家券商2024年文化建设年报在中国证券业协会网站公布。 （图：国泰海通、东吴证券文化建设年报内页） （图：中金公司、华泰证券、广发证券、中国银河证券文化建设年报内页） 党建引领仍是各内资券商文化建设年报最鲜明的共性之一，不少券商创新了党建形式，打造了特色党建品牌。例如，中泰证券打造了"红心如磐"党建品牌；华安证 券打造了"赤金"党建品牌；华源证券探索"智慧党建云+源文化+国企担当"融合发展模式；国泰海通证券则打造"融·党建"活动室特色宣传教育阵地，创新学习方式、 凝聚宣讲力量，推动党的创新理论深入一线、深入群众、深入人心。 打造廉洁文化，加强员工职业道德建设也是诸多券商近一年文化建设工作的重点之一。2024年9月，中国证券业协会修订发布了新版《证券从业人员职业道德准 则》，旨在引导证券从业人员珍惜职业声誉、恪守职业道德。 自2019年证券基金行业文化建设拉开序幕以来，今年已是各券商第四年提交文化建设年报。相比前三年，今年券商提交的文化建设年报更为体系化，案例更为丰 富，年报排版与设计精美度也直线上升。 从内容与形式来看，券商文化建设工作"卷"出新高度，一些券商新创设了党建、廉洁从业等子品牌，通过打 ...

国金证券党委书记、董事长冉云日前在接受上海证券报记者专访时表示，此次金融政策"组合拳"的广度 和力度超出市场预期，三大部门通过货币、监管、市场工具的多维协同，释放了"稳预期、强信心"的明 确信号，既针对当前外部冲击提供对冲，也通过制度性改革为资本市场中长期高质量发展奠定基础。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ ◎记者 王彦琳 近期，中国人民银行、金融监管总局、中国证监会联合推出一揽子金融政策，从货币政策、金融监管、 资本市场建设等多维度发力，贯彻落实中央政治局会议"要持续稳定和活跃资本市场"的决策部署。 他说，稳定和活跃资本市场，要构建"制度稳、资金活、监管准、创新强"的良性循环。短期需通过政 策"组合拳"提振信心，中长期则需依靠制度变革与市场生态优化，实现从"政策市"向"价值市"的转型。 政策"组合拳"重塑资本市场生态 开栏语 5月7日，中国人民银行、金融监管总局、中国证监会在国新办新闻发布会上推出了一揽子金融政策，稳 预期、强信心。如何落实一系列政策举措，持续稳定和活跃资本市场，即日起，本报推出"券商掌门人 谈'持续稳定和活跃资本市场'"栏目，邀请券商董事长深入探讨 ...

2025年5月22日，本公司兑付了该期短期融资券本息共计人民币 1,011,794,520.55元。 特此公告。 国金证券股份有限公司 国金证券股份有限公司 关于2024年度第六期短期融资券兑付完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 国金证券股份有限公司（以下简称"本公司"）于2024年10月24日 发行了2024年度第六期短期融资券，发行金额为人民币10亿元，票面利 率为2.05%，发行期限为210天，兑付日为2025年5月22日。详见公司于2024 年10月25日在上海证券交易所网站（www.sse.com.cn）披露的《关于2024 年度第六期短期融资券发行结果公告》以及2025年5月15日登载于中国货 币网（www.chinamoney.com.cn）、上海清算所网站（www.shclearing.com ）的《国金证券股份有限公司2024年度第六期短期融资券兑付公告》。 董事会 证券代码：600109 证券简称：国金证券 公告编号：临 2025－36 二〇二五年五月二十三日 ...

Core Viewpoint - The company Jiangxi Mubang High-Tech Co., Ltd. has had part of its fundraising account frozen due to legal actions, which may impact its operational and investment projects [2][4]. Group 1: Basic Situation - The company has opened fundraising accounts at several banks, including Ganzhou Bank, Beijing Bank, China Everbright Bank, and Citic Bank, where funds have been judicially frozen [2][3]. - As of May 15, 2025, the total amount frozen across these accounts is 34.89 million yuan, with specific accounts showing varying amounts frozen [3][4]. Group 2: Reasons for Judicial Freezing - The freezing of funds is primarily due to lawsuits involving Jiangxi Chantuo Commercial Factoring Co., Ltd. and other companies, stemming from a failure to make timely payments related to a domestic factoring contract [4]. Group 3: Impact on the Company - As of May 15, 2025, the remaining balance in the company's fundraising accounts is 132.36 million yuan, with 97.47 million yuan available for use after accounting for the frozen funds [4]. - Other than the five accounts that are frozen, the remaining fundraising accounts are operational and can be used normally [4].

Quantitative Models and Construction Methods 1. Model Name: Micro-Cap Timing Model - **Model Construction Idea**: This model uses mid-term risk warning indicators to monitor market timing for micro-cap stocks, focusing on both market sentiment and fundamental indicators[29] - **Model Construction Process**: 1. Two key indicators are used: - **10-Year Treasury Yield YoY**: Measures the year-over-year change in 10-year treasury yields - **Volatility Crowding YoY**: Reflects market trading sentiment through changes in volatility 2. Risk thresholds are set for these indicators: - 10-Year Treasury Yield YoY threshold: 0.3 - Volatility Crowding YoY threshold: 0 3. If either indicator exceeds its threshold, a risk warning signal is triggered. Conversely, if both indicators fall below their thresholds, the risk warning is lifted[29][30][36] - **Model Evaluation**: The model currently does not trigger any risk warnings, suggesting a stable environment for holding micro-cap stocks[29] --- Model Backtesting Results 1. Micro-Cap Timing Model - **10-Year Treasury Yield YoY**: -28.69% (below the risk threshold of 0.3)[30] - **Volatility Crowding YoY**: -50.09% (below the risk threshold of 0)[30] --- Quantitative Factors and Construction Methods 1. Factor Name: Value Factor - **Factor Construction Idea**: Captures undervaluation by comparing financial metrics to market prices[51] - **Factor Construction Process**: 1. **Key Metrics**: - **SP_TTM**: Revenue over the past 12 months divided by the latest market capitalization - **EP_FY0**: Current annual report's expected net profit divided by the latest market capitalization - **Sales2EV**: Revenue over the past 12 months divided by enterprise value 2. These metrics are aggregated to form the value factor, with higher values indicating greater undervaluation[51] 2. Factor Name: Size Factor - **Factor Construction Idea**: Measures the impact of company size on stock performance[51] - **Factor Construction Process**: 1. **Key Metrics**: - **LN_MktCap**: Natural logarithm of free-float market capitalization - **BP_LR**: Book value per share divided by the latest market price - **EP_FTTM**: Forward 12-month expected earnings divided by the latest market price 2. These metrics are combined to represent the size factor, with smaller companies typically expected to outperform[51] 3. Factor Name: Volatility Factor - **Factor Construction Idea**: Captures the impact of price and return volatility on stock performance[51] - **Factor Construction Process**: 1. **Key Metrics**: - **IV_CAPM**: Residual volatility from the CAPM model - **IV_FF**: Residual volatility from the Fama-French three-factor model - **Price_Chg20D**: 20-day price change 2. These metrics are aggregated to form the volatility factor, with lower volatility generally preferred[51] 4. Factor Name: Reversal Factor - **Factor Construction Idea**: Exploits the tendency of stocks to revert to their mean after extreme movements[51] - **Factor Construction Process**: 1. **Key Metrics**: - **Price_Chg40D**: 40-day price change - **Price_Chg60D**: 60-day price change - **Price_Chg120D**: 120-day price change 2. These metrics are aggregated to form the reversal factor, with negative values indicating stronger reversal potential[51] 5. Factor Name: Convertible Bond Valuation Factor - **Factor Construction Idea**: Evaluates convertible bonds based on their valuation and relationship with underlying stocks[44] - **Factor Construction Process**: 1. **Key Metrics**: - **Parity Premium**: Difference between the convertible bond price and its parity value - **Underlying Stock Factors**: Includes growth, quality, and valuation metrics of the underlying stock 2. These metrics are combined to assess the attractiveness of convertible bonds[44][49] --- Factor Backtesting Results 1. Value Factor - **IC Mean**: Positive across multiple stock pools, with notable performance in the financial and real estate sectors[39][40] - **Multi-Long-Short Returns**: Positive returns observed in the past week[39][42] 2. Size Factor - **IC Mean**: Strong performance in the CSI 300 stock pool[39][41] - **Multi-Long-Short Returns**: Expected to improve as market risk appetite increases[40] 3. Volatility Factor - **IC Mean**: Stable positive returns in the A-share stock pool[39][42] - **Multi-Long-Short Returns**: Demonstrated consistent performance in recent weeks[39][42] 4. Reversal Factor - **IC Mean**: Outperformed in the CSI 500 and CSI 1000 stock pools[39][41] - **Multi-Long-Short Returns**: Positive returns observed in the past week[39][42] 5. Convertible Bond Valuation Factor - **Multi-Long-Short Returns**: Positive returns for value and valuation factors in the convertible bond market[44][48]

Core Insights - The exoskeleton robot industry is expected to accelerate its commercialization process by 2025 due to improved cost-performance ratios, the rise of rental models for climbing assistance, and increased financing for startups [2] - Exoskeleton robots have diverse applications, including rehabilitation, industrial assistance, outdoor sports, and military use [3] Group 1: Definition and Development of Exoskeleton Robots - Exoskeleton robots are wearable intelligent mechanical devices that enhance or restore human movement capabilities through collaboration of motors, sensors, and control systems [1] - They can be categorized by structure (upper limb, lower limb, full-body) and by driving methods (hydraulic, pneumatic, motor-driven, and hybrid) [1] - The development history includes three phases: exploration and experimentation (1960-1980), gradual development (1980-2000), and breakthrough technological advancements (2000-present) [1] Group 2: Factors Driving Commercialization in 2025 - Advancements in AI technology have improved the intelligence of exoskeleton robots, enabling precise judgment of human walking intentions and required joint torque [2] - The emergence of rental models for climbing assistance is enhancing service offerings, with notable implementations in popular tourist destinations [2] - Increased financing for startups is expected to help expand product lines and upgrade core technologies, facilitating accelerated mass production [2] Group 3: Application Scenarios - In the rehabilitation sector, exoskeleton robots can assist the 17 million new stroke patients globally each year, including 2.5 million in China [3] - In the industrial sector, with 114 million workers in China, exoskeletons can reduce physical strain and improve work efficiency [3] - The outdoor sports market is projected to reach 1.36 billion participants by 2026, where exoskeletons can enhance physical capabilities and reduce injury risks [3] - In the military domain, exoskeleton robots can enhance individual soldier capabilities and improve logistical efficiency [3] Group 4: Technological Progress of Domestic Companies - Listed companies in the exoskeleton robot sector include Zhenjiang Co., Xiangyu Medical, Weisi Medical, Jinggong Technology, and Tanshan, which have obtained relevant patents or are in the final testing stages [4] - Many startups are in the Pre-IPO stage but have launched exoskeleton products in various commercial applications [4] - The acceleration of financing for startups in 2025 is expected to enhance their technological development and market positioning [4]

国金证券股份有限公司唐执敬,李蓉近期对申能股份（600642）进行研究并发布了研究报告《上海火电龙头，优质资产赋能高分红》，首次覆盖申 能股份给予买入评级，目标价10.03元。 电力需求、煤价下行程度、电力市场化改革进展、其他非流动金融资产持有期间的投资收益不及预期等 申能股份 投资逻辑 煤价下行周期，区位优势加码火电利润弹性。销售端来看：火电资产的"区位优势"主要体现为区域供需格局和行业集中度，在市场化交易中影响 量价。①区域供需：支撑性电源供给受限而用电负荷刚性增长，预计上海本地电力供需偏紧格局将延续至26年；21年以来公司煤机利用小时数不 低于4800小时，且未来2年有望维持高位。②竞争格局：上海发电侧行业集中度高而稳定，公司/华能/上电/宝钢合计火电装机市占率达80%以上， 且互相交叉持股。电力供需偏紧+火电行业集中度较高，上海25年中长期市场化交易电价降幅小于行业平均。成本端来看：预计25年国内煤炭产 量净增约0.70~0.75亿吨，进口量小幅回落；商品煤消费需求净增量在0.5亿吨左右，供需宽松。预计全年市场煤均价在700元/吨左右，同比-156元/ 吨。测算当北港5500大卡煤价中枢分别为720/ ...